Anna Kan
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
Papers in
- Hepatology 17
- Hepatocellular Carcinoma Treatment and Prognosis 16
- Liver Disease and Transplantation 5
-
- RNA modifications and cancer 6
- Co-authors
- Ming Shi (22 shared papers)Rong Guo (12 shared papers)Wei Wei (9 shared papers)Minke He (15 shared papers)QiJiong Li (10 shared papers)ZhiCheng Lai (16 shared papers)Haijing Deng (3 shared papers)Ming Zhao (2 shared papers)
In The Last Decade
Anna Kan
36 papers receiving 919 citations
Anna Kan's Hit Papers
Peers
Comparison fields: 5 of 70
- Hepatology 361
- Cancer Research 244
- Oncology 275
- Pathology and Forensic Medicine 151
- Immunology 136
Countries citing papers authored by Anna Kan
This map shows the geographic impact of Anna Kan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kan more than expected).
Fields of papers citing papers by Anna Kan
This network shows the impact of papers produced by Anna Kan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kan. The network helps show where Anna Kan may publish in the future.
Co-authors
The 25 scholars most cited alongside Anna Kan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 129 | |
| 2 | 2020 | 128 | |
| 3 | Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial Hit paper breakdown → | 2022 | 119 |
| 4 | 2020 | 59 | |
| 5 | 2021 | 51 | |
| 6 | 2019 | 51 | |
| 7 | 2019 | 33 | |
| 8 | 2020 | 32 | |
| 9 | 2019 | 28 | |
| 10 | 2021 | 25 | |
| 11 | 2019 | 23 | |
| 12 | 2019 | 23 | |
| 13 | 2022 | 22 | |
| 14 | 2023 | 17 | |
| 15 | 2020 | 17 | |
| 16 | 2018 | 16 | |
| 17 | 2018 | 14 | |
| 18 | 2021 | 14 | |
| 19 | 2022 | 12 | |
| 20 | 2019 | 12 |
About Anna Kan
Anna Kan is a scholar working on Hepatology, Molecular Biology, Oncology, Pathology and Forensic Medicine and Epidemiology, having authored 38 papers that have together received 927 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer Mechanisms and Therapy (9 papers), Liver Disease Diagnosis and Treatment (8 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), RNA modifications and cancer (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Liver Disease and Transplantation (5 papers) and Peptidase Inhibition and Analysis (4 papers). The work is most often cited by research in Hepatology (361 citations), Cancer Research (244 citations), Oncology (275 citations), Pathology and Forensic Medicine (151 citations) and Immunology (136 citations). Anna Kan has collaborated with scholars based in China, Canada and Hong Kong. Frequent co-authors include Ming Shi, Rong Guo, Wei Wei, Minke He, QiJiong Li, ZhiCheng Lai, Haijing Deng, Ming Zhao, Dongsheng Wen and Shaolong Li. Their work appears in journals such as Journal of Clinical Oncology, Cancer Cell International, Journal of Cancer, Cell Death and Disease and Cancer Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.